A report from the National Alliance of Healthcare Purchaser Coalitions detailed the common concerns employers have regarding implementing biosimilars within their health care plans and outlined how they could take charge and make a difference.
When it comes to getting biosimilars on formulary lists, employers may have more power than they realize and could take a number of big actions to ensure they are achieving the greatest savings, according to a report from the National Alliance of Healthcare Purchaser Coalitions (National Alliance).
The report detailed biosimilar concerns and successes of 7 regional coalitions and over 60 employers and compiled a comprehensive list of key actions that employers could take to overcome obstacles to biosimilar adoption.
Reduced barriers could produce about $25 billion in savings over 10 years, which could total $133 billion by 2025 as policy makers take on a greater role in encouraging greater biosimilar adoption, according to the Association for Accessible Medicines.
The National Alliance conducted a presurvey, roundtable discussion and a post survey to gain intelligence on the challenges that employers are facing in regard to adopting biosimilars and the concerns surrounding pharmacy-benefit trends.
The National Alliance aggregated the results, finding 5 key themes for action:
Some employers raised concerns that adding biosimilars and reference biologics to health plans might worry or confuse plan members about whether their treatment regimens would be interrupted or if the move would trigger restrictions on reimbursements.
The National Alliance recommended that employers create an additional tier or preferred reimbursement for biosimilars and reference biologics to take advantage of savings related to unit prices. Employers could also add biosimilars to the branded tier without needing to change cost-sharing or co-pay models.
Employers expressed heavy agreement that consultants, pharmacy benefit managers (PBMs), and insurance companies “sold” them on standardized formularies by telling them that they would have to pay extra to customize formulary lists if they wanted to add biosimilars or new reference drugs.
However, while some PBMs are restricting biosimilars from being added to formularies, employers can require them to be added without additional fees because there are not enough products to warrant a separate fee or a difference in administering claims. The National Alliance recommended that employers take control of formulary management, implement a formulary that is not driven by rebates, and request an audit of the current formulary.
Other recommendations that the organization had for employers included:
The report also included some top priorities for employers and purchasers to keep in mind over the next 2 years:
Reference
Rehayem M, Jung A. Improving drug management: employer strategies on biosimilars. National Alliance of Healthcare Purchaser Coalitions. February 22, 2022. Accessed February 24, 2022. https://connect.nationalalliancehealth.org/viewdocument/improving-drug-management-employer
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.